Expression of immunomodulating molecules by recombinant viruses: Can the immunogenicity of live virus vaccines be improved?

Expert Review of Vaccines

Volumn 1, Issue 2, 2002, Pages 233-245

  Bukreyev, Alexander ^b   Belyakov, Igor M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antibodies; Chemokines; Cytokines; Cytotoxic T lymphocyte; Immunity; Infectious diseases; Vaccines; Viruses

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; LIVE VACCINE; MUCIN 1; RECOMBINANT VACCINE; RECOMBINANT VACCINIA VIRUS; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; EBOLA VIRUS; FOWLPOX VIRUS; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MEASLES VIRUS; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; HUMANS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; VIRUSES;

EID: 0013042361     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.2.233     Document Type: Review

References (97)

1. Collins PL, Whitehead SS, Bukreyev A et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv. Virus Res. 54, 423-451 (1999).
2. Siegrist C, Saddallah F, Tougne C, Martinez X, Kovarik J, Lambert PH. Induction of neonatal TH1 and CTL responses by live viral vaccines: a role for replication patterns within antigen-presenting cells? Vaccine 16, 1473-1478 (1998).
3. Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur. J. Immunol. 26, 1489-1496 (1996).
4. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145, 3796-3806 (1990).
5. Seko Y, Takahashi N, Yagita H, Okumura K, Yazaki Y. Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus b3. J. Pathol. 183, 105-108 (1997).
6. Kramer JM, LaRussa P, Tsai WC et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 108, E39 (2001).
7. Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol. Rev. 170, 151-172 (1999).
8. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1, 209-219 (2001).
9. Belyakov IM, Hel Z, Kelsall B et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7, 1320-1326 (2001).
10. Flexner C, Hugin A, Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330, 259-262 (1987).
11. Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BE. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329, 545-546 (1987).
12. Flexner C, Moss B, London WT, Murphy BR. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine 8, 17-21 (1990).
13. Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw IA. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur. J. Immunol. 20, 157-161 (1990).
14. Karupiah G, Woodhams CE, Blanden RV, Ramshaw LA. Immunobiology of infection with recombinant vaccinia virus encoding murine IL-2. Mechanisms of rapid viral clearance in immunocompetent mice. J. Immunol. 147, 4327-4332 (1991).
15. Bukreyev A, Whitehead SS, Prussin C, Murphy BR, Collins PL. Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity and production of other cytokines. J. Virol. 74, 7151-7157 (2000).
16. Gundlach BR, Linhart H, Ditmer U et al. Construction, replication and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J. Virol. 71, 2225-2232 (1997).
17. Bukreyev A, Whitehead SS, Bukreyeva N, Murphy BR, Collins PL. Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proc. Natl Acad. Sci. USA 96, 2367-2372 (1999).
18. Johnson TR, Fischer JE, Graham BS. Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine. J. Gen. Virol. 82, 2107-2116 (2001).
19. Giavedoni LD, Yilma T. Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon. J. Virol. 70, 2247-2251 (1996).
20. Giavedoni I, Ahmad S, Jones L, Yilma T. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J. Virol. 71, 866-872 (1997).
21. Giavedoni LD, Imhoof JD, Velasquillo MC, Parodi LM, Hodara VL. Expression of the interleukin-18 gene from rhesus macaque by the simian immunodeficiency virus does not result in increased viral replication. J. Interferon Cytokine Res. 21, 173-180 (2001).
22. Karaca K, Sharma JM, Winslow BJ et al. Recombinant fowlpox viruses coexpressing chicken Type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses. Vaccine 16, 1496-1503 (1998).
23. Rautenschlein S, Sharma JM, Winslow BJ, McMillen J, Junker D, Cochran M. Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants. Vaccine 18, 426-433 (1999).
24. Leong KH, Ramshaw IA, Ramsay AJ. Interleukin-7 enhances cell-mediated immune responses in vivo in an interleukin-2-dependent manner. Viral Immunol. 10, 1-9 (1997).
25. Kurilla MG, Swaminathan S, Welsh RM, Kieff E, Brutkiewicz RR. Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. J. Virol. 67, 7623-7628 (1993).
26. Bukreyev A, Belyakov IM, Berzofsky JA, Murphy BR, Collins PL. Granulocytemacrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol. 75, 12128-12140 (2001).
27. Tamashiro VG, Perez HH, Griffin DE. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr. Infect. Dis. J. 6, 451-454 (1987).
28. Hussey GD, Goddard EA, Hughes J et al. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J. Infect. Dis. 173, 1320-1326 (1996).
29. Singh M, Billeter MA. A recombinant measles virus expressing biologically active human interleukin-12. J. Gen. Virol. 80, 101-106 (1999).
30. Ramsay AJ, Husband AJ, Ramshaw IA et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264, 561-563 (1994).
31. Ramsay AJ, Leong KH, Boyle D, Ruby J, Ramshaw IA. Enhancement of mucosal IgA responses by interleukins 5 and 6 encoded in recombinant vaccine vectors. Reprod. Fertil. Dev. 6, 389-392 (1994).
32. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J. Virol. 68, 8125-8130 (1994).
33. Tian J, Olcott AP, Hanssen LR, Zekzer D, Middleton B, Kaufman DL. Infectious Th1 and Th2 autoimmunity in diabetes-prone mice. Immunol. Rev. 164, 119-127 (1998).
34. Cameron MJ, Arreaza GA, Zucker P et al. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol. 159, 4686-4692 (1997).
35. Chapman NM, Kim KS, Tracy S et al. Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. J. Virol. 74, 7952-7962 (2000).
36. Manickan E, Francotte M, Kuklin N et al. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J. Virol. 69, 4711-4716 (1995).
37. Kuklin NA, Daheshia M, Marconi PC et al. Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines. Virology 240, 245-253 (1998).
38. Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J. Virol. 70, 7103-7107 (1996).
39. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75, 1205-1210 (2001).
40. Valmori D, Levy F, Miconnet I et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 164, 1125-1131 (2000).
41. Hodge JW, McLaughlin JP, Kantor JA, Schlorn J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15, 759-768 (1997).
42. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59, 676-683 (1999).
43. Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 20, 1862-1869 (2002).
44. Yamazaki M, Zhang R, Straus FH et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther. 9, 64-74 (2002).
45. Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with Type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94, 842-849 (2001).
46. Schlom J, Hodge JW. The diversity of T-cell co-stimulation in the induction of antitumor immunity. Immunol. Rev. 170, 73-84 (1999).
47. Kalus RM, Kantor JA, Gritz L et al. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 17, 893-903 (1999).
48. Akagi J, Hodge JW, McLaughlin JP et al. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J. Immunother. 20, 38-47 (1997).
49. Chamberlain RS, Carroll MW, Bronte V et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56, 2832-2836 (1996).
50. Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12 and a model tumor antigen. J. Natl Cancer Inst. 90, 1881-1887 (1998).
51. Liu Y, Zhang X, Zhang W et al. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther. 9, 202-208 (2002).
52. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96, 91-99 (2000).
53. Kikuchi T, Worgall S, Singh R, Moore MA, Crystal RG. Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nat. Med. 6, 1154-1159 (2000).
54. Bukreyev A, Camargo E, Collins PL. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J. Virol. 70, 6634-6641 (1996).
55. Ahlers JD, Belyakov LM, Matsui S, Berzofsky JA. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13, 897-908 (2001).
56. Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sci. USA 96, 4512-4517 (1999).
57. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74, 7651-7655 (2000).
58. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17, 253-258 (1999).
59. Biragyn A, Surenhu M, Yang D et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 167, 6644-6653 (2001).
60. Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW. DNA vaccines encoding HIV-1 gp120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood In press (2002).
61. Cheers C, Janas M, Ramsay A, Ramshaw I. Use of recombinant viruses to deliver cytokines influencing the course of experimental bacterial infection. Immunol. Cell Biol. 77, 324-330 (1999).
62. Rao JB, Chamberlain RS, Bronte V et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol. 156, 3357-3365 (1996).
63. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59, 5800-5807 (1999).
64. Zhu M, Terasawa H, Gulley J et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 61, 3725-3734 (2001).
65. Aung S, Tang YW, Graham BS. Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo. J. Virol. 73, 8944-8949 (1999).
66. Perera LP, Goldman CK, Waldmann TA. Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc. Natl Acad. Sci. USA 98, 5146-5151 (2001).
67. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327 (1998).
68. Barouch DH, Santra S, Schmitz JE et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
69. McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res. 56, 2361-2367 (1996).
70. Kim JJ, Yang JS, Manson KH, Weiner DB. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 19, 2496-2505 (2001).
71. Kim JJ, Yang JS, Montaner L, Lee DJ, Chalian AA, Weiner DB. Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo. J. Interferon Cytokine Res. 20, 311-319 (2000).
72. Mack DG, Jaffe HA. Effect of administration of a recombinant adenovirus expressing the genes for IFN-gamma and interleukin-12 on acute murine toxoplasmosis. J. Interferon Cytokine Res. 21, 777-783 (2001).
73. Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD. gamma-Interferon plays a key role in T-cell-induced tumor regression. Cancer Res. 53, 833-839 (1993).
74. Hara I, Taguchi I, Miyake H, Hara S, Gotoh A, Kamidono S. Effects of retinoic acid and interferon-gamma on expression of the retinoic acid receptor in mouse renal cell carcinoma. Int. J. Oncol. 19, 959-962 (2001).
75. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2, 129-135 (1995).
76. Yamano S, Scott DE, Huang LY et al. Protection from experimental endotoxemia by a recombinant adeno-associated virus encoding interleukin 10. J. Gene Med. 3, 450-457 (2001).
77. Nakase H, Okazaki K, Tabata Y et al. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J. Pharmacol. Exp. Ther. 301, 59-65 (2002).
78. Kaufman HL, Rao JB, Irvine KR et al. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J. Immunother. 22, 489-496 (1999).
79. Lee CT, Wu S, Ciernik IF et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocytemacrophage colony-stimulating factor. Hum. Gene Ther. 8, 187-193 (1997).
80. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol. 158, 3947-3958 (1997).
81. Kim JJ, Trivedi NN, Nottingham LK et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol. 28, 1089-1103 (1998).
82. Colmenero P, Chen M, Chanos-Velez E, Liljestrom P, Jondal M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int. J. Cancer 98, 554-560 (2002).
83. Gonzalo RM, Rodriguez JR, Rodriguez D, Gonzalez-Aseguinolaza G, Larraga V, Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect. 3, 701-711 (2001).
84. Mazzolini G, Narvaiza I, Perez-Diez A et al. Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther. 8, 259-26 (2001).
85. Belyakov IM, Ahlers JD, Brandwein BY et al. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102, 2072-2081 (1998).
86. Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J. Immunol. 165, 6454-6462 (2000).
87. Ansari AA, Mayne AE, Sundstrom JB et al. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIV mac251-infected rhesus macaques. J. Virol. 76, 1731-1743 (2002).
88. Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA. Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor-alpha synergize for IL-12R expression at low antigen dose. Int. Immunol. 13, 1433-1442 (2001).
89. Glansbeek HL, Haagmans BL, te Lintelo EG et al. Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus. J. Gen. Virol. 83, 1-10 (2002).
90. Lui VW, Falo LD, Jr., Huang L. Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. J. Gene Med. 3, 384-393 (2001).
91. Boyer JD, Cohen AD, Ugen KE et al. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. AIDs 14, 1515-1522 (2000).
92. Sin JI, Kim JJ, Arnold RL et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J. Immunol. 162, 2912-2921 (1999).
93. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J. Immunol. 161, 6977-6984 (1998).
94. Cao S, Troutt AB, Rustum YM. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res. 58, 1695-1699 (1998).
95. Evans R, Fuller JA, Christianson G, Krupke DM, Troutt AB. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell Immunol. 179, 66-73 (1997).
96. Meazza R, Lollini PL, Nanni P et al. Gene transfer of a secreTable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int. J. Cancer. 87, 574-581 (2000).
97. Xin KQ, Hamajima K, Sasaki S et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 17, 858-866 (1999).